Response to induction therapy and patients who received allogeneic SCT according to TCR and genotypic subsets
. | Patients, N (%) . | CR after 1 course (%) . | Early death . | CR after salvage . | Overall CR rate (%) . | SCT in 1st CR¶ . | SCT in 2nd CR¶ . | Total SCT CR, %¶ . |
|---|---|---|---|---|---|---|---|---|
| All patients | 91 | 66 (73) | 4 | 15/21 | 81 (89) | 11 (5/6) | 16 (15/1) | 30 |
| TCR subsets* | ||||||||
| Immature | 31 (34) | 14 (45)‡ | 3 | 9/14 | 23 (74)‡ | 4 (1/3) | 2 (1/1) | 19 |
| Pre-αβ | 29 (32) | 28 (97)‡ | 0 | 1/1 | 29 (100)§ | 2 (2/0) | 9 (9/0) | 40 |
| TCR-αβ+ | 18 (20) | 14 (78) | 1 | 3/3 | 17 (94) | 2 (1/1) | 1 (1/0) | 17 |
| TCR-αβ+ | 13 (14) | 10 (77) | 0 | 2/3 | 12 (92) | 3 (1/2) | 4 (4/0) | 54 |
| Genotypic subsets† | ||||||||
| CALM-AF10 | 8 (10) | 4 (50) | 0 | 3/4 | 7 (87.5) | 2 (1/1) | 1 (0/1) | 38 |
| SIL-TAL1 | 11 (14) | 11 (100)§ | 0 | — | 11 (100) | 0 | 3 (3/0) | 27 |
| HOX11 | 11 (14) | 11 (100)§ | 0 | — | 11 (100) | 2 (2/0) | 4 (4/0) | 54 |
| HOX11L2 | 10 (12) | 5 (50) | 3 | 1/2 | 6 (60)§ | 1 (0/1) | 2 (2/0) | 30 |
| TAL1 | 22 (32) | 18 (82) | 0 | 3/4 | 21 (95) | 4 (2/2) | 2 (2/0) | 27 |
| LYL | 8 (12) | 3 (37.5)∥ | 1 | 2/4 | 5 (62.5)∥ | 3 (2/1) | 0 | 27 |
| LMO2 | 15 (22) | 7 (47)∥ | 1 | 4/7 | 11 (73) | 1 (0/1) | 2 (2/0) | 20 |
. | Patients, N (%) . | CR after 1 course (%) . | Early death . | CR after salvage . | Overall CR rate (%) . | SCT in 1st CR¶ . | SCT in 2nd CR¶ . | Total SCT CR, %¶ . |
|---|---|---|---|---|---|---|---|---|
| All patients | 91 | 66 (73) | 4 | 15/21 | 81 (89) | 11 (5/6) | 16 (15/1) | 30 |
| TCR subsets* | ||||||||
| Immature | 31 (34) | 14 (45)‡ | 3 | 9/14 | 23 (74)‡ | 4 (1/3) | 2 (1/1) | 19 |
| Pre-αβ | 29 (32) | 28 (97)‡ | 0 | 1/1 | 29 (100)§ | 2 (2/0) | 9 (9/0) | 40 |
| TCR-αβ+ | 18 (20) | 14 (78) | 1 | 3/3 | 17 (94) | 2 (1/1) | 1 (1/0) | 17 |
| TCR-αβ+ | 13 (14) | 10 (77) | 0 | 2/3 | 12 (92) | 3 (1/2) | 4 (4/0) | 54 |
| Genotypic subsets† | ||||||||
| CALM-AF10 | 8 (10) | 4 (50) | 0 | 3/4 | 7 (87.5) | 2 (1/1) | 1 (0/1) | 38 |
| SIL-TAL1 | 11 (14) | 11 (100)§ | 0 | — | 11 (100) | 0 | 3 (3/0) | 27 |
| HOX11 | 11 (14) | 11 (100)§ | 0 | — | 11 (100) | 2 (2/0) | 4 (4/0) | 54 |
| HOX11L2 | 10 (12) | 5 (50) | 3 | 1/2 | 6 (60)§ | 1 (0/1) | 2 (2/0) | 30 |
| TAL1 | 22 (32) | 18 (82) | 0 | 3/4 | 21 (95) | 4 (2/2) | 2 (2/0) | 27 |
| LYL | 8 (12) | 3 (37.5)∥ | 1 | 2/4 | 5 (62.5)∥ | 3 (2/1) | 0 | 27 |
| LMO2 | 15 (22) | 7 (47)∥ | 1 | 4/7 | 11 (73) | 1 (0/1) | 2 (2/0) | 20 |
Criteria for positivity are given in “Patients, materials, and methods.” — indicates not applicable.
All 91 patients were studied and patients from each subset were compared with those from the other 3 subsets.
HOX11, HOX11L2, SIL-TAL1, and CALM-AF10 testing was performed in 81 of 91 patients; patients from each subset were compared to all other patients tested. LYL, LMO2, and TAL1 testing was performed in 69 patients.
P < .01.
P < .05.
P < .10.
Parenthetical values indicate numbers of patients who achieved CR after 1 induction or 1 induction followed by 1 salvage course, respectively.